CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials
Although CNS disease was excluded from initial trials of CART in ALL, this retrospective review shows CART is effective in clearing CNS disease and is not associated with increased risk of neurotoxicity.